BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18397679)

  • 1. Advanced CML: therapeutic options for patients in accelerated and blast phases.
    Shah NP
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S31-S36. PubMed ID: 18397679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
    Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).
    Klyuchnikov E; Kröger N; Brummendorf TH; Wiedemann B; Zander AR; Bacher U
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):301-10. PubMed ID: 19744571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
    Irvine DA; Heaney NB; Holyoake TL
    Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options in imatinib-resistant chronic myelogenous leukemia.
    Marshall HM; Hammond JM
    Ann Pharmacother; 2008 Feb; 42(2):259-64. PubMed ID: 18212257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
    le Coutre P; Schwarz M; Kim TD
    Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance and relapse with imatinib in CML: causes and consequences.
    Deininger M
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of chronic myelogenous leukemia in 2004].
    Hochhaus A; Berger U; Hehlmann R
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D
    Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia blast crisis arises from progenitors.
    Michor F
    Stem Cells; 2007 May; 25(5):1114-8. PubMed ID: 17218393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting to the stem of chronic myeloid leukaemia.
    Savona M; Talpaz M
    Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current role of stem cell transplantation in chronic myeloid leukaemia.
    Gratwohl A; Heim D
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.